Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease

By sjmartinez • October 21, 2022

Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2022 Oct 20:gfac283. doi: 10.1093/ndt/gfac283. Epub ahead of print. PMID: 36264305.

Tags: cardiovascular disease, Chronic kidney disease, diabetes mellitus, glucagon-like peptide-1 receptor agonist, Nephrology, nonsteroidal mineralocorticoid receptor antagonist, Publications, sodium-glucose cotransporter-2 inhibitor

Clinical characteristics and CKD care delivery in African American and American Indian or Alaska Native patients: A real-world cohort study

Mayhand KN, Alicic RZ, Kornowske LM, Jones CR, Daratha KB, Reynolds CL, Nicholas SB, Thorpe RJ Jr, Bui AAT, Norris KC, Tuttle KR. Clinical characteristics[...]

The End Kidney Deaths Act-Reply

Mueller TF, Matamoros MA, Danovitch GM. The End Kidney Deaths Act-Reply. JAMA. 2025 Jul 21. doi: 10.1001/jama.2025.8243. Epub ahead of print. PMID: 40690250.

Population risk predictors of major adverse kidney events attributed to focal segmental glomerulosclerosis from the CURE-CKD registry

Nicholas SB, Kornowske LM, Jones CR, Daratha KB, Alicic RZ, Reynolds CL, Neumiller JJ, Bensink ME, Gong W, Norris KC, Tuttle KR. Population risk predictors[...]